These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

708 related items for PubMed ID: 27736859

  • 1. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW, Horvath H.
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [Abstract] [Full Text] [Related]

  • 2. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
    Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, Chen H, Zang N, Liao Y, Ye L, Liang H.
    AIDS Res Ther; 2016; 13(1):30. PubMed ID: 27617024
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S, Losa García JE, Berenguer Berenguer J, Martínez Sesmero JM, Cenoz Gomis S, Graefenhain R, Lopez Sanchez-Cambronero D, Parrondo Garcia FJ.
    Farm Hosp; 2017 Sep 01; 41(5):601-610. PubMed ID: 28847249
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C, Pappa K, Wynne B, Min S, Nichols G, SINGLE Investigators.
    N Engl J Med; 2013 Nov 07; 369(19):1807-18. PubMed ID: 24195548
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
    Pialoux G, Marcelin AG, Cawston H, Guilmet C, Finkielsztejn L, Laurisse A, Aubin C.
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb 07; 18(1):83-91. PubMed ID: 28741965
    [Abstract] [Full Text] [Related]

  • 7. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
    Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, Hulgan T, Raffanti S, Haas DW, Sterling TR, Koethe JR.
    J Acquir Immune Defic Syndr; 2017 Dec 15; 76(5):527-531. PubMed ID: 28825943
    [Abstract] [Full Text] [Related]

  • 8. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
    Greig SL, Deeks ED.
    Drugs; 2015 Apr 15; 75(5):503-14. PubMed ID: 25698454
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A, Rutherford GW, Siegfried N.
    Cochrane Database Syst Rev; 2010 Oct 06; (10):CD008740. PubMed ID: 20927777
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S, Tafazzoli A, Dorman E, Rosenblatt L, Villasis-Keever A, Sorensen S.
    J Med Econ; 2015 Oct 06; 18(10):763-76. PubMed ID: 25934146
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
    Nickel K, Halfpenny NJA, Snedecor SJ, Punekar YS.
    BMC Infect Dis; 2021 Feb 26; 21(1):222. PubMed ID: 33637050
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
    Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, Koteff JA, Wynne B, Hopking J, Granier C, Aboud M.
    Antivir Ther; 2017 Feb 26; 22(4):295-305. PubMed ID: 28401876
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N, Poli A, Galli L, Muccini C, Mastrangelo A, Dell'Acqua R, Maillard M, Bossolasco S, Cinque P, Lazzarin A, Castagna A, Gianotti N.
    Int J Antimicrob Agents; 2020 Mar 26; 55(3):105893. PubMed ID: 31926287
    [Abstract] [Full Text] [Related]

  • 18. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P, Sension M, Arribas J, Duiculescu D, Florence E, Hung CC, Wilkin T, Vanveggel S, Stevens M, Deckx H, ECHO and THRIVE Study Groups.
    Clin Infect Dis; 2014 Aug 01; 59(3):425-34. PubMed ID: 24729492
    [Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
    Tremblay G, Chounta V, Piercy J, Holbrook T, Garib SA, Bukin EK, Punekar YS.
    Value Health Reg Issues; 2018 Sep 01; 16():74-80. PubMed ID: 30296624
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
    Radford M, Parks DC, Ferrante S, Punekar Y.
    AIDS; 2019 Sep 01; 33(11):1739-1749. PubMed ID: 31180906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.